MMTZFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as RLFTY
MindMaze Therapeutics Holding SA
Financials through fiscal 2023, year ended Dec 31, 2023Last filing: 20-F on Apr 30, 2024
$0.19−0.00 (-0.22%)
Close on Oct 19, 2026
Share price
−$3.3470 (−94.55%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
MindMaze Therapeutics Holding SA saw revenue fall 11.0% to CHF 6.33M over fiscal 2023. Free cash flow was -CHF 18.06M.
Revenue
CHF 6.33M
-11.0% vs. a year earlier
Operating income
-CHF 110.83M
FY2023
Free cash flow
-CHF 18.06M
FY2023
EPS, diluted
-8.35 CHF
FY2023
Key statistics
Valuation at the latest close; fundamentals over fiscal 2023, balances at Dec 31, 2023
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- CHF 6.33M
- EPS, diluted
- -8.35 CHF
- Free cash flow
- -CHF 18.06M
Valuation needs the share price. It fills in once daily prices are connected and converted from CHF.
Four years at a glance
Fiscal years 2020 to 2023, CHF
Revenue
CHF 6.33M-11.0% YoY
Operating income
-CHF 110.83M
EPS, diluted
-8.35 CHF
Free cash flow
-CHF 18.06M
Reported period